3. Acute and sub-chronic toxicological evaluation of Boga -TN tablets in experimental animals
Nội dung chính của bài viết
Tóm tắt
Boga-TN is a formula originating from herbal medicines that are used to treat liver disorders; however, its toxicity is not yet investigated. Therefore, this study was conducted to assess the acute and sub-chronic toxicity of Boga-TN tablets in experimental animals. Acute toxicity study was performed via Swiss mice, with a single oral dose, and followed up to seven days according to World Health Organization Guidance. No sign of acute oral toxicity was detected, and the LD50 Boga-TN was estimated to be more than 60.38 g/kg. Based onobtained results , the sub-chronic toxicity study was carried out in Wistar rats for 4 consecutive weeks by oral administration at the doses of 0.77 and 2.31 g/kg/day. After treatment, no significant treatment-related abnormalities were observed at both doses of Boga-TN, compared to the control group, except lower neutrophil but higher lymphocyte values were observed in the treated animals. Histopathology assessment did not show any significant variation between control and treatment groups during the study period.
Chi tiết bài viết
Từ khóa
Acute toxicity, Sub-chronic toxicity, Boga-TN tablets, experimental animals.
Tài liệu tham khảo
2. Gish RG, Bui TD, Nguyen CTK, et al. Liver disease in Viet Nam: Screening, surveillance, management and education: A 5-year plan and call to action. J Gastroenterol Hepatol. 2012; 27(2): 238-247. doi:10.1111/j.1440-1746.2011.06974.x.
3. Radha K. Dhiman MD, DM, MAMS, FACG. Herbal Medicines for Liver Diseases | SpringerLink. Digestive Diseases and Sciences. 2005; 50: 1807-1812.
4. Stickel F, Hellerbrand C. Herbs to treat liver diseases: More than placebo? Clin Liver Dis (Hoboken). 2016 Jan 21; 6(6): 136-138. doi: 10.1002/cld.515.
5. Wat E, Ng CF, Wong ECW, et al. The hepatoprotective effect of the combination use of Fructus Schisandrae with statin--A preclinical evaluation. J Ethnopharmacol. 2016; 178: 104-114. doi:10.1016/j.jep.2015.12.004.
6. WHO. Working group on the safety and efficacy of herbal medicine”, Report of regional office for the western pacific of the World Health Organization. 2000.
7. Litchfield. J.T, Wilcoxon. F. A simplified method of evaluating dose-effect experiments. Journal of Pharmacology and Experimental Therapeutics. 1949; 96: 99-113.
8. Deore A, Dhumane J, Wagh R, Sonawane R. The Stages of Drug Discovery and Development Process. Asian J Pharm Res Dev. 2019; 7: 62-67. doi:10.22270/ajprd.v7i6.616.
9. Ator MA, Mallamo JP, Williams M. Overview of drug discovery and development. Curr Protoc Pharmacol. 2006; Chapter 9:Unit9.9. doi:10.1002/0471141755.ph0909s35.
10. Chen X, Cao J, Sun Y, et al. Ethanol extract of Schisandrae chinensis fructus ameliorates the extent of experimentally induced atherosclerosis in rats by increasing antioxidant capacity and improving endothelial dysfunction. Pharm Biol. 2018; 56(1): 612-619. doi:10.1080/13880209.2018.1523933.
11. Petterino C, Argentino-Storino A. Clinical chemistry and haematology historical data in control Sprague-Dawley rats from pre-clinical toxicity studies. Exp Toxicol Pathol. 2006; 57(3): 213-219. doi:10.1016/j.etp.2005.10.002.
12. Lin L, Ni B, Lin H, et al. Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: a review. J Ethnopharmacol. 2015; 159: 158-183. doi:10.1016/j.jep.2014.11.009.
13. Saahene ROsei, Agbo E, Barnes P, et al. A Review: Mechanism of Phyllanthus urinaria in Cancers-NF-κB, P13K/AKT, and MAPKs Signaling Activation. Evid-Based Complement Altern Med ECAM. 2021; 2021: 4514342. doi:10.1155/2021/4514342.
14. Yang K, Qiu J, Huang Z, et al. A comprehensive review of ethnopharmacology, phytochemistry, pharmacology, and pharmacokinetics of Schisandra chinensis (Turcz.) Baill. and Schisandra sphenanthera Rehd. et Wils. J Ethnopharmacol. 2022; 284: 114759. doi:10.1016/j.jep.2021.114759.